GlassScriptPhysician profile
Sarah Hoopes
NPI 1730614348
$1,201.90
in general payments reported to CMS, 2019-2025
22 companies · $441 in 2025
The $441 reported for 2025 was more than what 77% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $201 · 2022: $224 · 2023: $58.91 · 2024: $277 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $777.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $777.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $215.71 | 2021-2023 | Iovera, Exparel |
| Biotissue Holdings INC. | $156.25 | 2025 | |
| Myovant Sciences INC. | $125.93 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $93.74 | 2023-2025 | Myfembree |
| Medtronic, INC. | $79.58 | 2022-2025 | Signia |
| Mayne Pharma Commercial LLC | $62.91 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.23 | 2022-2025 | |
| Coopersurgical, INC. | $42.12 | 2024 | Paragard T 380a |
| Baxter Healthcare | $40.84 | 2024 | Perclot |
| Hologic Sales and Service, LLC | $40.20 | 2025 | Fluent Fluid Management System, Myosure Tissue Removal Device, Omni Hysteroscope |
| Octapharma USA, INC. | $39.76 | 2025 | Fibryga |
| Evofem Biosciences, INC. | $38.15 | 2025 | Solosec, Phexx, Phexxi |
| Astellas Pharma US INC | $30.22 | 2024 | Veozah |
| Ethicon US, LLC | $23.20 | 2025 | Enseal |
| Mimedx Group, INC. | $22.64 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $21.90 | 2022 | |
| Glaxosmithkline, LLC. | $20.33 | 2022 | |
| Dilon Technologies, INC. | $19.69 | 2025 | Hemoblast Bellows |
| Millicent US INC | $19.25 | 2024 | Femring, Intrarosa |
| Organon LLC | $18.05 | 2024 | |
| Novo Nordisk INC | $16.43 | 2024 | Wegovy |
| Exeltis, USA INC. | $15.77 | 2024 | Slynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Hoopes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.